Prior to or when initiating Tenozet, and during treatment with Tenozet, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.

Recommended Dosage

Tenozet is a four-drug fixed dose combination product containing 800 mg of darunavir (DRV), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of Tenozet alafenamide (TAF). The recommended dosage of Tenozet is one tablet taken orally once daily with food in adults. For patients who are unable to swallow the whole tablet, Tenozet may be split into two pieces using a tablet-cutter, and the entire dose should be consumed immediately after splitting.

Not Recommended in Patients with Severe Renal Impairment

Tenozet is not recommended in patients with creatinine clearance below 30 mL per minute.

Not Recommended in Patients with Severe Hepatic Impairment

Tenozet is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).

Not Recommended During Pregnancy

Tenozet is not recommended during pregnancy because of substantially lower exposures of darunavir and cobicistat during pregnancy.

Tenozet should not be initiated in pregnant individuals. An alternative regimen is recommended for those who become pregnant during therapy with Tenozet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Tenozet (cobicistat / darunavir / emtricitabine / Tenozet alafenamide)

During Pregnancy
Drug Interactions
Pricing & Coupons
En Español
Drug class: antiviral combinations

Consumer resources

Tenozet
Tenozet (Advanced Reading)

Professional resources

Tenozet (AHFS Monograph)
Tenozet (FDA)

Related treatment guides

HIV Infection

What other drugs will affect Tenozet?

Tenozet can harm your kidneys. This effect is increased when you also use certain other medicines, including: antivirals, chemotherapy, injected antibiotics, medicine for bowel disorders, medicine to prevent organ transplant rejection, and some pain or arthritis medicines (including aspirin, Tylenol, Advil, and Aleve).

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Tenozet, especially other HIV or AIDS medications, such as:

atazanavir;
didanosine; or
lopinavir and ritonavir.

This list is not complete. Other drugs may interact with Tenozet, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Tenozet interactions

sponsored

Acyclovir-Valacyclovir: May increase the serum concentration of Tenozet Products. Tenozet Products may increase the serum concentration of Acyclovir-Valacyclovir. Monitor therapy

Adefovir: May diminish the therapeutic effect of Tenozet Products. Adefovir may increase the serum concentration of Tenozet Products. Tenozet Products may increase the serum concentration of Adefovir. Avoid combination

Aminoglycosides: May increase the serum concentration of Tenozet Products. Tenozet Products may increase the serum concentration of Aminoglycosides. Monitor therapy

Atazanavir: Tenozet Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenozet Disoproxil Fumarate. Management: Must use boosted atazanavir in adults; give combo (atazanavir/ritonavir or atazanavir/cobicistat with Tenozet) as a single daily dose with food. Pediatric patients, pregnant patients, and users of H2-blockers require other dose changes. Consider therapy modification

Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. Monitor therapy

Cidofovir: May increase the serum concentration of Tenozet Products. Tenozet Products may increase the serum concentration of Cidofovir. Monitor therapy

Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. Avoid combination

Cobicistat: May enhance the adverse/toxic effect of Tenozet Products. More specifically, cobicistat may impair proper Tenozet monitoring and dosing. Monitor therapy

Darunavir: Tenozet Disoproxil Fumarate may increase the serum concentration of Darunavir. Darunavir may increase the serum concentration of Tenozet Disoproxil Fumarate. Monitor therapy

Diclofenac (Systemic): May enhance the nephrotoxic effect of Tenozet Products. Management: Seek alternatives to this combination whenever possible. Avoid use of Tenozet with multiple NSAIDs or any NSAID given at a high dose. Consider therapy modification

Didanosine: Tenozet Disoproxil Fumarate may diminish the therapeutic effect of Didanosine. Tenozet Disoproxil Fumarate may increase the serum concentration of Didanosine. Management: Avoid use of Tenozet disoproxil fumarate and didanosine when possible. If combined in adults with CrCL greater than 60 mL/min, decrease didanosine to 250 mg daily if 60 kg or more or to 200 mg if less than 60 kg. Avoid if CrCL is less than 60 mL/min. Consider therapy modification

Ganciclovir-Valganciclovir: Tenozet Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenozet Products. Monitor therapy

Ledipasvir: May increase the serum concentration of Tenozet Disoproxil Fumarate. Management: Avoidance of this combination is recommended under some circumstances. Refer to full monograph for details. Consider therapy modification

Lopinavir: May enhance the nephrotoxic effect of Tenozet Disoproxil Fumarate. Lopinavir may increase the serum concentration of Tenozet Disoproxil Fumarate. Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenozet Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of Tenozet with multiple NSAIDs or any NSAID given at a high dose. Consider therapy modification

Orlistat: May decrease the serum concentration of Antiretroviral Agents. Monitor therapy

Simeprevir: Tenozet Disoproxil Fumarate may decrease the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Tenozet Disoproxil Fumarate. Monitor therapy

Tipranavir: Tenozet Disoproxil Fumarate may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenozet Disoproxil Fumarate. Monitor therapy

Velpatasvir: May increase the serum concentration of Tenozet Disoproxil Fumarate. Monitor therapy

Voxilaprevir: Tenozet Disoproxil Fumarate may increase the serum concentration of Voxilaprevir. Voxilaprevir may increase the serum concentration of Tenozet Disoproxil Fumarate. Monitor therapy

sponsored

Reviews

The results of a survey conducted on ndrugs.com for Tenozet are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tenozet. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet

Consumer reported doses

No survey data has been collected yet

Consumer reviews

There are no reviews yet. Be the first to write one!

Information checked by Dr. Sachin Kumar, MD Pharmacology

Tenozet Dosage

Dosage of Tenozet in details